PDF(Pubmed)
Abstract：
Oral treprostinil, approved for the treatment of pulmonary arterial hypertension, remains an attractive option in combination with other medications to delay disease progression and improve exercise capacity. However, patients are often challenged with the ability to overcome adverse effects as outpatients and reach effective doses in a timely manner. We describe a case of a 47-year-old female on oral treprostinil who presented to the clinic with worsening symptoms of disease, necessitating higher dosing. This patient was previously uptitrated outpatient with oral treprostinil, which had allowed her to remain stable for years. Once uptitrated with additional intravenous therapy, the oral treprostinil dose was gradually further increased to the new goal dosage, resulting in improvements in symptoms and right ventricular function. This case highlights the versatility of dose optimization of oral treprostinil with rapid bridging through intravenous therapy.
摘要：
口服曲前列环素，批准用于治疗肺动脉高压，与其他药物联合使用，以延缓疾病进展和提高运动能力，仍然是一个有吸引力的选择。然而,作为门诊患者，患者经常面临克服不良反应并及时达到有效剂量的能力的挑战。我们描述了一名47岁的女性口服曲前列环素的病例，该患者出现在临床上，疾病症状恶化，需要更高的剂量。该患者先前在门诊患者中口服曲前列环素，这让她多年来保持稳定。一旦增加额外的静脉治疗，口服曲前列环素剂量逐渐进一步增加到新的目标剂量，改善症状和右心室功能。此案例突出了口服曲前列环素剂量优化的多功能性，并通过静脉内治疗快速桥接。
